查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1239542

创伤性脑损伤(TBI)评估市场:按用户,诊断类型(CT扫描,MRI,颅内压监测,脑组织氧张力):全球机会分析行业预测,2021-2031

Traumatic brain injuries assessment Market By End-user, By Diagnostic Type (CT-Scan, MRI, Intracranial Pressure Monitoring, Partial Pressure of Oxygen in Brain Tissue, Others): Global Opportunity Analysis and Industry Forecast, 2021-2031
出版日期: | 出版商: Allied Market Research | 英文 250 Pages | 商品交期: 2-3个工作天内

价格

到 2021 年，全球脑外伤 (TBI) 评估市场价值将达到 95.7 亿美元，预计到 2031 年将产生 183.736 亿美元的收入，复合年增长率为 7.0%。

创伤性脑损伤 (TBI) 评估市场的增长是印度的一个重大公共卫生问题。 创伤性脑损伤导致活跃的年轻成年人死亡、受伤和残疾。 印度因 TBI 遭受了无法量化的巨大经济损失。 在印度，TBI 预计会随着汽车的普及和城市化进程的加快而增加。 世界卫生组织 (WHO) 最近发布的《道路交通伤害预防、暴力与健康全球报告》强调了世界各地伤害问题的严重程度以及如何实施预防、管理和康復计划。它明确了需要做什么紧急设计和评估。 印度是预防不是优先事项的国家之一。

TBI 会对执行功能和自我控制产生不利影响。 控制与压力和焦虑相关的行为的能力称为自我调节。 患有 TBI 的人可能会发现很难保持冷静，很难等待轮到他们，并且在陌生的环境中会情绪高涨。 执行功能是指涉及计划、记忆、目标设定、注意力和服从指令的高级大脑功能。 由于患有 TBI 的人很容易混淆和健忘，因此学习新信息、完成文书工作和使用公共交通工具可能很困难。

市场进入者采用最新技术和推出新产品预计将在预测期内加速市场扩张。 例如，BioDirection, Inc. 的 NanoDx 系统是一种快速即时 (POC) 诊断，可在不到两分钟的时间内准确诊断出脑震盪/TBI。

虽然这项由国家残疾、独立生活和康復研究所 (NIDILRR) 资助的研究仍在进行中，但初步研究结果表明，这种流行病已经影响社会隔离、日常生活中断、认知能力。对脑损伤患者产生重大影响，包括对 由社区服务办公室资助的创伤性脑损伤技术援助和资源中心 (TBI TARC) 已着手进一步调查 COVID-19 如何影响脑损伤患者。 TBI 咨询领导 (TAL) 小组的五名成员接受了 TBI TARC 的质询。 TAL 组的目的是规定 TBI TARC 的优先级。

内容

第 1 章介绍

第 2 章执行摘要

第 3 章市场概述

  • 市场定义和范围
  • 主要发现
    • 主要投资领域
  • 波特的五力分析
  • 市场动态
    • 促进因素
    • 约束因素
    • 机会
  • 分析 COVID-19 对市场的影响
  • 价值链分析
  • 主要监管分析
  • 专利情况
  • 监管准则
  • 市场份额分析

第 4 章创伤性脑损伤 (TBI) 评估市场：按最终用户分类

  • 概览
    • 市场规模和预测
  • 医院
    • 主要市场趋势、增长动力和机遇
    • 市场规模和预测：按地区
    • 市场份额分析：按国家/地区分类
  • 诊断中心
    • 主要市场趋势、增长动力和机遇
    • 市场规模和预测：按地区
    • 市场份额分析：按国家/地区分类
  • 其他
    • 主要市场趋势、增长动力和机遇
    • 市场规模和预测：按地区
    • 市场份额分析：按国家/地区分类

第 5 章创伤性脑损伤 (TBI) 评估市场：按诊断类型

  • 概览
    • 市场规模和预测
  • CT扫描
    • 主要市场趋势、增长动力和机遇
    • 市场规模和预测：按地区
    • 市场份额分析：按国家/地区分类
  • 核磁共振
    • 主要市场趋势、增长动力和机遇
    • 市场规模和预测：按地区
    • 市场份额分析：按国家/地区分类
  • 颅内压监测
    • 主要市场趋势、增长动力和机遇
    • 市场规模和预测：按地区
    • 市场份额分析：按国家/地区分类
  • 脑组织氧分压 (pBrO2)
    • 主要市场趋势、增长动力和机遇
    • 市场规模和预测：按地区
    • 市场份额分析：按国家/地区分类
  • 其他
    • 主要市场趋势、增长动力和机遇
    • 市场规模和预测：按地区
    • 市场份额分析：按国家/地区分类

第 6 章创伤性脑损伤 (TBI) 评估市场：按地区

  • 概览
    • 市场规模和预测
  • 北美
    • 主要趋势和机会
    • 北美市场规模和预测：按最终用户分类
    • 北美市场规模和按诊断类型预测
    • 北美市场规模和预测：按国家/地区分类
      • 美国
      • 主要市场趋势、增长动力和机遇
      • 最终用户的市场规模和预测
      • 按诊断类型划分的市场规模和预测
      • 加拿大
      • 主要市场趋势、增长动力和机遇
      • 最终用户的市场规模和预测
      • 按诊断类型划分的市场规模和预测
      • 墨西哥
      • 主要市场趋势、增长动力和机遇
      • 最终用户的市场规模和预测
      • 按诊断类型划分的市场规模和预测
  • 欧洲
    • 主要趋势和机会
    • 欧洲市场规模和预测：按最终用户分类
    • 欧洲市场规模和按诊断类型预测
    • 欧洲市场规模和预测：按国家/地区分类
      • 德国
      • 主要市场趋势、增长动力和机遇
      • 最终用户的市场规模和预测
      • 按诊断类型划分的市场规模和预测
      • 英国
      • 主要市场趋势、增长动力和机遇
      • 最终用户的市场规模和预测
      • 按诊断类型划分的市场规模和预测
      • 法国
      • 主要市场趋势、增长动力和机遇
      • 最终用户的市场规模和预测
      • 按诊断类型划分的市场规模和预测
      • 西班牙
      • 主要市场趋势、增长动力和机遇
      • 最终用户的市场规模和预测
      • 按诊断类型划分的市场规模和预测
      • 意大利
      • 主要市场趋势、增长动力和机遇
      • 最终用户的市场规模和预测
      • 按诊断类型划分的市场规模和预测
      • 其他欧洲
      • 主要市场趋势、增长动力和机遇
      • 最终用户的市场规模和预测
      • 按诊断类型划分的市场规模和预测
  • 亚太地区
    • 主要趋势和机会
    • 亚太市场规模和预测：按最终用户分类
    • 亚太市场规模和预测：按诊断类型
    • 亚太市场规模和预测：按国家/地区分类
      • 中国
      • 主要市场趋势、增长动力和机遇
      • 最终用户的市场规模和预测
      • 按诊断类型划分的市场规模和预测
      • 日本
      • 主要市场趋势、增长动力和机遇
      • 最终用户的市场规模和预测
      • 按诊断类型划分的市场规模和预测
      • 印度
      • 主要市场趋势、增长动力和机遇
      • 最终用户的市场规模和预测
      • 按诊断类型划分的市场规模和预测
      • 韩国
      • 主要市场趋势、增长动力和机遇
      • 最终用户的市场规模和预测
      • 按诊断类型划分的市场规模和预测
      • 澳大利亚
      • 主要市场趋势、增长动力和机遇
      • 最终用户的市场规模和预测
      • 按诊断类型划分的市场规模和预测
      • 其他亚太地区
      • 主要市场趋势、增长动力和机遇
      • 最终用户的市场规模和预测
      • 按诊断类型划分的市场规模和预测
  • 拉丁美洲/中东/非洲
    • 主要趋势和机会
    • LAMEA 市场规模和预测：按最终用户分类
    • LAMEA 市场规模和按诊断类型预测
    • LAMEA 市场规模和预测：按国家/地区分类
      • 巴西
      • 主要市场趋势、增长动力和机遇
      • 最终用户的市场规模和预测
      • 按诊断类型划分的市场规模和预测
      • 沙特阿拉伯
      • 主要市场趋势、增长动力和机遇
      • 最终用户的市场规模和预测
      • 按诊断类型划分的市场规模和预测
      • 阿拉伯联合酋长国
      • 主要市场趋势、增长动力和机遇
      • 最终用户的市场规模和预测
      • 按诊断类型划分的市场规模和预测
      • 南非
      • 主要市场趋势、增长动力和机遇
      • 最终用户的市场规模和预测
      • 按诊断类型划分的市场规模和预测
      • 其他拉丁美洲/中东/非洲
      • 主要市场趋势、增长动力和机遇
      • 最终用户的市场规模和预测
      • 按诊断类型划分的市场规模和预测

第 7 章竞争格局

  • 介绍
  • 关键成功策略
  • 排名前 10 位的玩家产品映射
  • 比赛仪表板
  • 竞争热图
  • 2021 年最佳球员排名

第 8 章公司简介

  • brainscope company inc.
  • NOVASIGNAL CORPORATION
  • Integra LifeSciences Holdings Corporation
  • Natus Medical Incorporated
  • Boston Scientific Corporation
  • Koninklijke Philips N.V.
  • BioDirection, Inc.
  • Nihon Kohden Corp.
  • RAUMEDIC AG
  • Compumedics Ltd.
Product Code: A31382

The global traumatic brain injuries assessment market size was $9,570 million in 2021 and is predicted to expand at a CAGR of 7.0% % by generating a revenue of $18,373.6 million by 2031.

Traumatic brain injuries assessment market growth is a significant public health issue in India. They contribute to the demise, harm, and disabling of young, active members of society. India suffers huge economic losses due to TBIs, yet they are unquantifiable. TBIs will rise in India as it moves toward greater growth and development in terms of motorization and urbanization. The World Health Organization's recent world reports on road traffic injury prevention and violence &health make clear how serious the problem of injuries is getting around the world and how urgently programs for prevention, management, and rehabilitation need to be designed and evaluated. India is one nation that has not prioritized prevention.

TBIs negatively affect executive function and self-control. The ability to control stress- and anxiety-related behavior is known as self-regulation. For someone with a TBI, this can involve difficulty settling down, difficulty waiting their turn, or having overpowering emotions in strange settings. Executive functioning refers to higher-order brain functions that are involved in planning, recalling, setting goals, focusing attention, and obeying directions. TBI sufferers may easily become disoriented or forget things, and they may find it challenging to learn new information, complete paperwork, or use public transportation.

The adoption of the most recent technologies and the launch of new products by market participants are expected to accelerate market expansion during the forecast period. For instance, Bio Direction, Inc.'s NanoDx system is a quick point-of-care (POC) diagnostic that accurately diagnoses concussions/TBIs in under two minutes.

The study, which is being funded by the National Institute on Disability, Independent Living, and Rehabilitation Research (NIDILRR), is still in progress, but preliminary findings indicate that the pandemic has a significant impact on those who have had brain injuries, including social isolation, disruption of daily life, and effects on cognition. The Administration for Community Living-funded Traumatic Brain Damage Technical Assistance and Resource Center (TBI TARC) set out to further study how COVID-19 has affected people with brain injuries. The TBI Advisory and Leadership (TAL) group's five members were questioned by the TBI TARC. The TAL group's goal is to direct TBI TARC's priorities.

The key players profiled in this report include: Integra Lifesciences, BioDirection, Inc., Nihon Kohden Corp., Compumedics Ltd., InfraScan, Inc., Oculogica, Raumedic AG, Zagros Petrochemical Co., Koninklijke Philips N.V, Boston Scientific Corporation, and Elekta.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the traumatic brain injuries assessment market analysis from 2021 to 2031 to identify the prevailing traumatic brain injuries assessment market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the traumatic brain injuries assessment market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global traumatic brain injuries assessment market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By End-user

  • Hospital
  • Diagnostics Center
  • Others

By Diagnostic Type

  • CT-Scan
  • MRI
  • Intracranial Pressure Monitoring
  • Partial Pressure of Oxygen in Brain Tissue (pBrO2)
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • UAE
    • South Africa
    • Rest of LAMEA

Key Market Players

  • brainscope company inc.
  • NOVASIGNAL CORPORATION
  • Integra LifeSciences Holdings Corporation
  • Natus Medical Incorporated
  • Boston Scientific Corporation
  • Koninklijke Philips N.V.
  • BioDirection, Inc.
  • Nihon Kohden Corp.
  • RAUMEDIC AG
  • Compumedics Ltd.

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key market segments
  • 1.3.Key benefits to the stakeholders
  • 1.4.Research Methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
  • 3.3.Porter's five forces analysis
  • 3.4.Market dynamics
    • 3.4.1.Drivers
    • 3.4.2.Restraints
    • 3.4.3.Opportunities
  • 3.5.COVID-19 Impact Analysis on the market
  • 3.6.Value Chain Analysis
  • 3.7.Key Regulation Analysis
  • 3.8.Patent Landscape
  • 3.9.Regulatory Guidelines
  • 3.10.Market Share Analysis

CHAPTER 4: TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY END-USER

  • 4.1 Overview
    • 4.1.1 Market size and forecast
  • 4.2. Hospital
    • 4.2.1 Key market trends, growth factors and opportunities
    • 4.2.2 Market size and forecast, by region
    • 4.2.3 Market share analysis by country
  • 4.3. Diagnostics Center
    • 4.3.1 Key market trends, growth factors and opportunities
    • 4.3.2 Market size and forecast, by region
    • 4.3.3 Market share analysis by country
  • 4.4. Others
    • 4.4.1 Key market trends, growth factors and opportunities
    • 4.4.2 Market size and forecast, by region
    • 4.4.3 Market share analysis by country

CHAPTER 5: TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY DIAGNOSTIC TYPE

  • 5.1 Overview
    • 5.1.1 Market size and forecast
  • 5.2. CT-Scan
    • 5.2.1 Key market trends, growth factors and opportunities
    • 5.2.2 Market size and forecast, by region
    • 5.2.3 Market share analysis by country
  • 5.3. MRI
    • 5.3.1 Key market trends, growth factors and opportunities
    • 5.3.2 Market size and forecast, by region
    • 5.3.3 Market share analysis by country
  • 5.4. Intracranial Pressure Monitoring
    • 5.4.1 Key market trends, growth factors and opportunities
    • 5.4.2 Market size and forecast, by region
    • 5.4.3 Market share analysis by country
  • 5.5. Partial Pressure of Oxygen in Brain Tissue (pBrO2)
    • 5.5.1 Key market trends, growth factors and opportunities
    • 5.5.2 Market size and forecast, by region
    • 5.5.3 Market share analysis by country
  • 5.6. Others
    • 5.6.1 Key market trends, growth factors and opportunities
    • 5.6.2 Market size and forecast, by region
    • 5.6.3 Market share analysis by country

CHAPTER 6: TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY REGION

  • 6.1 Overview
    • 6.1.1 Market size and forecast
  • 6.2 North America
    • 6.2.1 Key trends and opportunities
    • 6.2.2 North America Market size and forecast, by End-user
    • 6.2.3 North America Market size and forecast, by Diagnostic Type
    • 6.2.4 North America Market size and forecast, by country
      • 6.2.4.1 U.S.
      • 6.2.4.1.1 Key market trends, growth factors and opportunities
      • 6.2.4.1.2 Market size and forecast, by End-user
      • 6.2.4.1.3 Market size and forecast, by Diagnostic Type
      • 6.2.4.2 Canada
      • 6.2.4.2.1 Key market trends, growth factors and opportunities
      • 6.2.4.2.2 Market size and forecast, by End-user
      • 6.2.4.2.3 Market size and forecast, by Diagnostic Type
      • 6.2.4.3 Mexico
      • 6.2.4.3.1 Key market trends, growth factors and opportunities
      • 6.2.4.3.2 Market size and forecast, by End-user
      • 6.2.4.3.3 Market size and forecast, by Diagnostic Type
  • 6.3 Europe
    • 6.3.1 Key trends and opportunities
    • 6.3.2 Europe Market size and forecast, by End-user
    • 6.3.3 Europe Market size and forecast, by Diagnostic Type
    • 6.3.4 Europe Market size and forecast, by country
      • 6.3.4.1 Germany
      • 6.3.4.1.1 Key market trends, growth factors and opportunities
      • 6.3.4.1.2 Market size and forecast, by End-user
      • 6.3.4.1.3 Market size and forecast, by Diagnostic Type
      • 6.3.4.2 UK
      • 6.3.4.2.1 Key market trends, growth factors and opportunities
      • 6.3.4.2.2 Market size and forecast, by End-user
      • 6.3.4.2.3 Market size and forecast, by Diagnostic Type
      • 6.3.4.3 France
      • 6.3.4.3.1 Key market trends, growth factors and opportunities
      • 6.3.4.3.2 Market size and forecast, by End-user
      • 6.3.4.3.3 Market size and forecast, by Diagnostic Type
      • 6.3.4.4 Spain
      • 6.3.4.4.1 Key market trends, growth factors and opportunities
      • 6.3.4.4.2 Market size and forecast, by End-user
      • 6.3.4.4.3 Market size and forecast, by Diagnostic Type
      • 6.3.4.5 Italy
      • 6.3.4.5.1 Key market trends, growth factors and opportunities
      • 6.3.4.5.2 Market size and forecast, by End-user
      • 6.3.4.5.3 Market size and forecast, by Diagnostic Type
      • 6.3.4.6 Rest of Europe
      • 6.3.4.6.1 Key market trends, growth factors and opportunities
      • 6.3.4.6.2 Market size and forecast, by End-user
      • 6.3.4.6.3 Market size and forecast, by Diagnostic Type
  • 6.4 Asia-Pacific
    • 6.4.1 Key trends and opportunities
    • 6.4.2 Asia-Pacific Market size and forecast, by End-user
    • 6.4.3 Asia-Pacific Market size and forecast, by Diagnostic Type
    • 6.4.4 Asia-Pacific Market size and forecast, by country
      • 6.4.4.1 China
      • 6.4.4.1.1 Key market trends, growth factors and opportunities
      • 6.4.4.1.2 Market size and forecast, by End-user
      • 6.4.4.1.3 Market size and forecast, by Diagnostic Type
      • 6.4.4.2 Japan
      • 6.4.4.2.1 Key market trends, growth factors and opportunities
      • 6.4.4.2.2 Market size and forecast, by End-user
      • 6.4.4.2.3 Market size and forecast, by Diagnostic Type
      • 6.4.4.3 India
      • 6.4.4.3.1 Key market trends, growth factors and opportunities
      • 6.4.4.3.2 Market size and forecast, by End-user
      • 6.4.4.3.3 Market size and forecast, by Diagnostic Type
      • 6.4.4.4 South Korea
      • 6.4.4.4.1 Key market trends, growth factors and opportunities
      • 6.4.4.4.2 Market size and forecast, by End-user
      • 6.4.4.4.3 Market size and forecast, by Diagnostic Type
      • 6.4.4.5 Australia
      • 6.4.4.5.1 Key market trends, growth factors and opportunities
      • 6.4.4.5.2 Market size and forecast, by End-user
      • 6.4.4.5.3 Market size and forecast, by Diagnostic Type
      • 6.4.4.6 Rest of Asia-Pacific
      • 6.4.4.6.1 Key market trends, growth factors and opportunities
      • 6.4.4.6.2 Market size and forecast, by End-user
      • 6.4.4.6.3 Market size and forecast, by Diagnostic Type
  • 6.5 LAMEA
    • 6.5.1 Key trends and opportunities
    • 6.5.2 LAMEA Market size and forecast, by End-user
    • 6.5.3 LAMEA Market size and forecast, by Diagnostic Type
    • 6.5.4 LAMEA Market size and forecast, by country
      • 6.5.4.1 Brazil
      • 6.5.4.1.1 Key market trends, growth factors and opportunities
      • 6.5.4.1.2 Market size and forecast, by End-user
      • 6.5.4.1.3 Market size and forecast, by Diagnostic Type
      • 6.5.4.2 Saudi Arabia
      • 6.5.4.2.1 Key market trends, growth factors and opportunities
      • 6.5.4.2.2 Market size and forecast, by End-user
      • 6.5.4.2.3 Market size and forecast, by Diagnostic Type
      • 6.5.4.3 UAE
      • 6.5.4.3.1 Key market trends, growth factors and opportunities
      • 6.5.4.3.2 Market size and forecast, by End-user
      • 6.5.4.3.3 Market size and forecast, by Diagnostic Type
      • 6.5.4.4 South Africa
      • 6.5.4.4.1 Key market trends, growth factors and opportunities
      • 6.5.4.4.2 Market size and forecast, by End-user
      • 6.5.4.4.3 Market size and forecast, by Diagnostic Type
      • 6.5.4.5 Rest of LAMEA
      • 6.5.4.5.1 Key market trends, growth factors and opportunities
      • 6.5.4.5.2 Market size and forecast, by End-user
      • 6.5.4.5.3 Market size and forecast, by Diagnostic Type

CHAPTER 7: COMPETITIVE LANDSCAPE

  • 7.1. Introduction
  • 7.2. Top winning strategies
  • 7.3. Product Mapping of Top 10 Player
  • 7.4. Competitive Dashboard
  • 7.5. Competitive Heatmap
  • 7.6. Top player positioning, 2021

CHAPTER 8: COMPANY PROFILES

  • 8.1 brainscope company inc.
    • 8.1.1 Company overview
    • 8.1.2 Key Executives
    • 8.1.3 Company snapshot
    • 8.1.4 Operating business segments
    • 8.1.5 Product portfolio
    • 8.1.6 Business performance
    • 8.1.7 Key strategic moves and developments
  • 8.2 NOVASIGNAL CORPORATION
    • 8.2.1 Company overview
    • 8.2.2 Key Executives
    • 8.2.3 Company snapshot
    • 8.2.4 Operating business segments
    • 8.2.5 Product portfolio
    • 8.2.6 Business performance
    • 8.2.7 Key strategic moves and developments
  • 8.3 Integra LifeSciences Holdings Corporation
    • 8.3.1 Company overview
    • 8.3.2 Key Executives
    • 8.3.3 Company snapshot
    • 8.3.4 Operating business segments
    • 8.3.5 Product portfolio
    • 8.3.6 Business performance
    • 8.3.7 Key strategic moves and developments
  • 8.4 Natus Medical Incorporated
    • 8.4.1 Company overview
    • 8.4.2 Key Executives
    • 8.4.3 Company snapshot
    • 8.4.4 Operating business segments
    • 8.4.5 Product portfolio
    • 8.4.6 Business performance
    • 8.4.7 Key strategic moves and developments
  • 8.5 Boston Scientific Corporation
    • 8.5.1 Company overview
    • 8.5.2 Key Executives
    • 8.5.3 Company snapshot
    • 8.5.4 Operating business segments
    • 8.5.5 Product portfolio
    • 8.5.6 Business performance
    • 8.5.7 Key strategic moves and developments
  • 8.6 Koninklijke Philips N.V.
    • 8.6.1 Company overview
    • 8.6.2 Key Executives
    • 8.6.3 Company snapshot
    • 8.6.4 Operating business segments
    • 8.6.5 Product portfolio
    • 8.6.6 Business performance
    • 8.6.7 Key strategic moves and developments
  • 8.7 BioDirection, Inc.
    • 8.7.1 Company overview
    • 8.7.2 Key Executives
    • 8.7.3 Company snapshot
    • 8.7.4 Operating business segments
    • 8.7.5 Product portfolio
    • 8.7.6 Business performance
    • 8.7.7 Key strategic moves and developments
  • 8.8 Nihon Kohden Corp.
    • 8.8.1 Company overview
    • 8.8.2 Key Executives
    • 8.8.3 Company snapshot
    • 8.8.4 Operating business segments
    • 8.8.5 Product portfolio
    • 8.8.6 Business performance
    • 8.8.7 Key strategic moves and developments
  • 8.9 RAUMEDIC AG
    • 8.9.1 Company overview
    • 8.9.2 Key Executives
    • 8.9.3 Company snapshot
    • 8.9.4 Operating business segments
    • 8.9.5 Product portfolio
    • 8.9.6 Business performance
    • 8.9.7 Key strategic moves and developments
  • 8.10 Compumedics Ltd.
    • 8.10.1 Company overview
    • 8.10.2 Key Executives
    • 8.10.3 Company snapshot
    • 8.10.4 Operating business segments
    • 8.10.5 Product portfolio
    • 8.10.6 Business performance
    • 8.10.7 Key strategic moves and developments

LIST OF TABLES

  • TABLE 1. GLOBAL TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY END-USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 2. TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET FOR HOSPITAL, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 3. TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET FOR DIAGNOSTICS CENTER, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 4. TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET FOR OTHERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 5. GLOBAL TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY DIAGNOSTIC TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 6. TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET FOR CT-SCAN, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 7. TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET FOR MRI, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 8. TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET FOR INTRACRANIAL PRESSURE MONITORING, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 9. TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET FOR PARTIAL PRESSURE OF OXYGEN IN BRAIN TISSUE (PBRO2), BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 10. TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET FOR OTHERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 11. TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 12. NORTH AMERICA TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY END-USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 13. NORTH AMERICA TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY DIAGNOSTIC TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 14. NORTH AMERICA TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 15. U.S. TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY END-USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 16. U.S. TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY DIAGNOSTIC TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 17. CANADA TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY END-USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 18. CANADA TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY DIAGNOSTIC TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 19. MEXICO TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY END-USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 20. MEXICO TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY DIAGNOSTIC TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 21. EUROPE TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY END-USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 22. EUROPE TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY DIAGNOSTIC TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 23. EUROPE TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 24. GERMANY TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY END-USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 25. GERMANY TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY DIAGNOSTIC TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 26. UK TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY END-USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 27. UK TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY DIAGNOSTIC TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 28. FRANCE TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY END-USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 29. FRANCE TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY DIAGNOSTIC TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 30. SPAIN TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY END-USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 31. SPAIN TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY DIAGNOSTIC TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 32. ITALY TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY END-USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 33. ITALY TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY DIAGNOSTIC TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 34. REST OF EUROPE TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY END-USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 35. REST OF EUROPE TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY DIAGNOSTIC TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 36. ASIA-PACIFIC TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY END-USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 37. ASIA-PACIFIC TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY DIAGNOSTIC TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 38. ASIA-PACIFIC TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 39. CHINA TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY END-USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 40. CHINA TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY DIAGNOSTIC TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 41. JAPAN TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY END-USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 42. JAPAN TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY DIAGNOSTIC TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 43. INDIA TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY END-USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 44. INDIA TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY DIAGNOSTIC TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 45. SOUTH KOREA TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY END-USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 46. SOUTH KOREA TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY DIAGNOSTIC TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 47. AUSTRALIA TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY END-USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 48. AUSTRALIA TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY DIAGNOSTIC TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 49. REST OF ASIA-PACIFIC TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY END-USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 50. REST OF ASIA-PACIFIC TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY DIAGNOSTIC TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 51. LAMEA TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY END-USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 52. LAMEA TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY DIAGNOSTIC TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 53. LAMEA TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 54. BRAZIL TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY END-USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 55. BRAZIL TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY DIAGNOSTIC TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 56. SAUDI ARABIA TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY END-USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 57. SAUDI ARABIA TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY DIAGNOSTIC TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 58. UAE TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY END-USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 59. UAE TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY DIAGNOSTIC TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 60. SOUTH AFRICA TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY END-USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 61. SOUTH AFRICA TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY DIAGNOSTIC TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 62. REST OF LAMEA TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY END-USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 63. REST OF LAMEA TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY DIAGNOSTIC TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 64. BRAINSCOPE COMPANY INC.: KEY EXECUTIVES
  • TABLE 65. BRAINSCOPE COMPANY INC.: COMPANY SNAPSHOT
  • TABLE 66. BRAINSCOPE COMPANY INC.: OPERATING SEGMENTS
  • TABLE 67. BRAINSCOPE COMPANY INC.: PRODUCT PORTFOLIO
  • TABLE 68. BRAINSCOPE COMPANY INC.: NET SALES
  • TABLE 69. BRAINSCOPE COMPANY INC.: KEY STRATERGIES
  • TABLE 70. NOVASIGNAL CORPORATION: KEY EXECUTIVES
  • TABLE 71. NOVASIGNAL CORPORATION: COMPANY SNAPSHOT
  • TABLE 72. NOVASIGNAL CORPORATION: OPERATING SEGMENTS
  • TABLE 73. NOVASIGNAL CORPORATION: PRODUCT PORTFOLIO
  • TABLE 74. NOVASIGNAL CORPORATION: NET SALES
  • TABLE 75. NOVASIGNAL CORPORATION: KEY STRATERGIES
  • TABLE 76. INTEGRA LIFESCIENCES HOLDINGS CORPORATION: KEY EXECUTIVES
  • TABLE 77. INTEGRA LIFESCIENCES HOLDINGS CORPORATION: COMPANY SNAPSHOT
  • TABLE 78. INTEGRA LIFESCIENCES HOLDINGS CORPORATION: OPERATING SEGMENTS
  • TABLE 79. INTEGRA LIFESCIENCES HOLDINGS CORPORATION: PRODUCT PORTFOLIO
  • TABLE 80. INTEGRA LIFESCIENCES HOLDINGS CORPORATION: NET SALES
  • TABLE 81. INTEGRA LIFESCIENCES HOLDINGS CORPORATION: KEY STRATERGIES
  • TABLE 82. NATUS MEDICAL INCORPORATED: KEY EXECUTIVES
  • TABLE 83. NATUS MEDICAL INCORPORATED: COMPANY SNAPSHOT
  • TABLE 84. NATUS MEDICAL INCORPORATED: OPERATING SEGMENTS
  • TABLE 85. NATUS MEDICAL INCORPORATED: PRODUCT PORTFOLIO
  • TABLE 86. NATUS MEDICAL INCORPORATED: NET SALES
  • TABLE 87. NATUS MEDICAL INCORPORATED: KEY STRATERGIES
  • TABLE 88. BOSTON SCIENTIFIC CORPORATION: KEY EXECUTIVES
  • TABLE 89. BOSTON SCIENTIFIC CORPORATION: COMPANY SNAPSHOT
  • TABLE 90. BOSTON SCIENTIFIC CORPORATION: OPERATING SEGMENTS
  • TABLE 91. BOSTON SCIENTIFIC CORPORATION: PRODUCT PORTFOLIO
  • TABLE 92. BOSTON SCIENTIFIC CORPORATION: NET SALES
  • TABLE 93. BOSTON SCIENTIFIC CORPORATION: KEY STRATERGIES
  • TABLE 94. KONINKLIJKE PHILIPS N.V.: KEY EXECUTIVES
  • TABLE 95. KONINKLIJKE PHILIPS N.V.: COMPANY SNAPSHOT
  • TABLE 96. KONINKLIJKE PHILIPS N.V.: OPERATING SEGMENTS
  • TABLE 97. KONINKLIJKE PHILIPS N.V.: PRODUCT PORTFOLIO
  • TABLE 98. KONINKLIJKE PHILIPS N.V.: NET SALES
  • TABLE 99. KONINKLIJKE PHILIPS N.V.: KEY STRATERGIES
  • TABLE 100. BIODIRECTION, INC.: KEY EXECUTIVES
  • TABLE 101. BIODIRECTION, INC.: COMPANY SNAPSHOT
  • TABLE 102. BIODIRECTION, INC.: OPERATING SEGMENTS
  • TABLE 103. BIODIRECTION, INC.: PRODUCT PORTFOLIO
  • TABLE 104. BIODIRECTION, INC.: NET SALES
  • TABLE 105. BIODIRECTION, INC.: KEY STRATERGIES
  • TABLE 106. NIHON KOHDEN CORP.: KEY EXECUTIVES
  • TABLE 107. NIHON KOHDEN CORP.: COMPANY SNAPSHOT
  • TABLE 108. NIHON KOHDEN CORP.: OPERATING SEGMENTS
  • TABLE 109. NIHON KOHDEN CORP.: PRODUCT PORTFOLIO
  • TABLE 110. NIHON KOHDEN CORP.: NET SALES
  • TABLE 111. NIHON KOHDEN CORP.: KEY STRATERGIES
  • TABLE 112. RAUMEDIC AG: KEY EXECUTIVES
  • TABLE 113. RAUMEDIC AG: COMPANY SNAPSHOT
  • TABLE 114. RAUMEDIC AG: OPERATING SEGMENTS
  • TABLE 115. RAUMEDIC AG: PRODUCT PORTFOLIO
  • TABLE 116. RAUMEDIC AG: NET SALES
  • TABLE 117. RAUMEDIC AG: KEY STRATERGIES
  • TABLE 118. COMPUMEDICS LTD.: KEY EXECUTIVES
  • TABLE 119. COMPUMEDICS LTD.: COMPANY SNAPSHOT
  • TABLE 120. COMPUMEDICS LTD.: OPERATING SEGMENTS
  • TABLE 121. COMPUMEDICS LTD.: PRODUCT PORTFOLIO
  • TABLE 122. COMPUMEDICS LTD.: NET SALES
  • TABLE 123. COMPUMEDICS LTD.: KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 1. SEGMENTATION OF TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET,2021-2031
  • FIGURE 2. TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET,2021-2031
  • FIGURE 3. TOP INVESTMENT POCKETS, BY REGION
  • FIGURE 4. PORTER FIVE-1
  • FIGURE 5. PORTER FIVE-2
  • FIGURE 6. PORTER FIVE-3
  • FIGURE 7. PORTER FIVE-4
  • FIGURE 8. PORTER FIVE-5
  • FIGURE 9. TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 10. VALUE CHAIN ANALYSIS
  • FIGURE 11. KEY REGULATION ANALYSIS
  • FIGURE 12. PATENT ANALYSIS BY COMPANY
  • FIGURE 13. PATENT ANALYSIS BY COUNTRY
  • FIGURE 14. REGULATORY GUIDELINES
  • FIGURE 15. MARKET SHARE ANALYSIS
  • FIGURE 16. TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET,BY END-USER,2021(%)
  • FIGURE 17. COMPARATIVE SHARE ANALYSIS OF HOSPITAL TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, 2021 AND 2031(%)
  • FIGURE 18. COMPARATIVE SHARE ANALYSIS OF DIAGNOSTICS CENTER TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, 2021 AND 2031(%)
  • FIGURE 19. COMPARATIVE SHARE ANALYSIS OF OTHERS TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, 2021 AND 2031(%)
  • FIGURE 20. TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET,BY DIAGNOSTIC TYPE,2021(%)
  • FIGURE 21. COMPARATIVE SHARE ANALYSIS OF CT-SCAN TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, 2021 AND 2031(%)
  • FIGURE 22. COMPARATIVE SHARE ANALYSIS OF MRI TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, 2021 AND 2031(%)
  • FIGURE 23. COMPARATIVE SHARE ANALYSIS OF INTRACRANIAL PRESSURE MONITORING TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, 2021 AND 2031(%)
  • FIGURE 24. COMPARATIVE SHARE ANALYSIS OF PARTIAL PRESSURE OF OXYGEN IN BRAIN TISSUE (PBRO2) TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, 2021 AND 2031(%)
  • FIGURE 25. COMPARATIVE SHARE ANALYSIS OF OTHERS TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, 2021 AND 2031(%)
  • FIGURE 26. TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET BY REGION,2021
  • FIGURE 27. U.S. TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET,2021-2031($MILLION)
  • FIGURE 28. CANADA TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET,2021-2031($MILLION)
  • FIGURE 29. MEXICO TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET,2021-2031($MILLION)
  • FIGURE 30. GERMANY TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET,2021-2031($MILLION)
  • FIGURE 31. UK TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET,2021-2031($MILLION)
  • FIGURE 32. FRANCE TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET,2021-2031($MILLION)
  • FIGURE 33. SPAIN TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET,2021-2031($MILLION)
  • FIGURE 34. ITALY TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET,2021-2031($MILLION)
  • FIGURE 35. REST OF EUROPE TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET,2021-2031($MILLION)
  • FIGURE 36. CHINA TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET,2021-2031($MILLION)
  • FIGURE 37. JAPAN TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET,2021-2031($MILLION)
  • FIGURE 38. INDIA TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET,2021-2031($MILLION)
  • FIGURE 39. SOUTH KOREA TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET,2021-2031($MILLION)
  • FIGURE 40. AUSTRALIA TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET,2021-2031($MILLION)
  • FIGURE 41. REST OF ASIA-PACIFIC TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET,2021-2031($MILLION)
  • FIGURE 42. BRAZIL TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET,2021-2031($MILLION)
  • FIGURE 43. SAUDI ARABIA TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET,2021-2031($MILLION)
  • FIGURE 44. UAE TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET,2021-2031($MILLION)
  • FIGURE 45. SOUTH AFRICA TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET,2021-2031($MILLION)
  • FIGURE 46. REST OF LAMEA TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET,2021-2031($MILLION)
  • FIGURE 47. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 48. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 49. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 50. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 51. COMPETITIVE DASHBOARD
  • FIGURE 52. COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
  • FIGURE 53. TOP PLAYER POSITIONING, 2021
  • FIGURE 54. BRAINSCOPE COMPANY INC..: NET SALES ($MILLION)
  • FIGURE 55. NOVASIGNAL CORPORATION.: NET SALES ($MILLION)
  • FIGURE 56. INTEGRA LIFESCIENCES HOLDINGS CORPORATION.: NET SALES ($MILLION)
  • FIGURE 57. NATUS MEDICAL INCORPORATED.: NET SALES ($MILLION)
  • FIGURE 58. BOSTON SCIENTIFIC CORPORATION.: NET SALES ($MILLION)
  • FIGURE 59. KONINKLIJKE PHILIPS N.V..: NET SALES ($MILLION)
  • FIGURE 60. BIODIRECTION, INC..: NET SALES ($MILLION)
  • FIGURE 61. NIHON KOHDEN CORP..: NET SALES ($MILLION)
  • FIGURE 62. RAUMEDIC AG.: NET SALES ($MILLION)
  • FIGURE 63. COMPUMEDICS LTD..: NET SALES ($MILLION)